Aquestive Therapeutics to Participate in Upcoming September Investor Conferences

WARREN, N.J., Sept. 01, 2026 — Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in four upcoming investor conferences in September 2026 as follows:

• 2026 Wells Fargo Healthcare Conference: available to host investor meetings on Tuesday, September 8th
• Cantor Healthcare Conference: fireside chat at 3:20 pm ET and available to host investor meetings on Wednesday, September 9th
• Citi’s 2026 Biopharma Back to School Summit: available to host investor meetings Thursday, September 10th.
• H.C. Wainwright 27th Annual Global Investor Conference: presentation at 9:00 am ET on Monday, September 14th and available to host investor meetings September 14th and Tuesday, September 15th

Webcasts of the fireside chat at the Cantor Healthcare Conference and the presentation at the H.C. Wainwright 27h Annual Global Investor Conference will be available under the “Events and Presentation” page of the Investors section of the Company’s website. A replay of the webcast will be available for 30 days following the event. For more information, please visit investors.aquestive.com.

About Aquestive Therapeutics, Inc.

Aquestive is a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies. The worldwide leader in delivering trusted, quality medications on oral film, Aquestive operates as both a developer of its own proprietary products and a Contract Development and Manufacturing Organization (CDMO) for licensees, with its headquarters in New Jersey and U.S.-based manufacturing facilities in Indiana. The Company is the exclusive manufacturer of four commercialized products marketed by its licensees across six continents using proprietary, best-in-class technologies like PharmFilm®. Aquestive's AdrenaVerse™ platform contains a library of more than 20 epinephrine prodrugs enabling the pursuit of various potential allergy and dermatological indications. The Company is advancing Anaphylm™ (dibutepinephrine) sublingual film for the treatment of severe allergic reactions, including anaphylaxis, and AQST-108 (epinephrine) topical gel for various potential dermatological conditions. For more information, visit Aquestive.com and follow us on LinkedIn.